Genetic Variation Associated With Survival Advantage in African Americans With HIV
... Duffy antigen receptor for chemokine (DARC) and
leukopenia have slower HIV-to-AIDS progression rates than ... (WBC) counts than persons of European ancestry.
leukopenia is one of several blood conditions observed ... is relatively unknown.
"Even though
leukopenia is tied to both African ancestry and faster ...
Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer
... of patients with NSCLC were
anemia (8 vs 7);
leukopenia (5 vs 28); neutropenia (5 vs ... of
patients with MPM were neutropenia (24 vs 4);
leukopenia (16 vs 1); anemia
(6 vs 0); thrombocytopenia (5 ... alone, respectively, were neutropenia (58 vs
16);
leukopenia (55 vs 20); anemia (33 vs 14); thrombocytopenia ...
ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection)
... of patients with NSCLC were
anemia (8 vs 7);
leukopenia (5 vs 28); neutropenia (5 vs ... of
patients with MPM were neutropenia (24 vs 4);
leukopenia (16 vs 1); anemia
(6 vs 0); thrombocytopenia (5 ... alone, respectively, were neutropenia (58 vs
16);
leukopenia (55 vs 20); anemia (33 vs 14); thrombocytopenia ...
New therapy with stem cells to treat Crohn's disease
... Initial Chemotherapy (Cyclophosphamide + G-CSF). In this initial phase,
leukopenia or reduction of the number of leukocytes (immune-system cells) in the ... until ready for transplant.
Second Chemotherapy. In this phase, total
leukopenia is induced; that is, the immune system is left devoid of leukocytes, ready ...
Novel therapeutic approaches may improve patient outcomes in several platelet disorders
... by 15 to 25 percent. Secondary objectives included safety, duration of
leukopenia and thrombocytopenia, and the number of red blood cell transfusions.
... no life-threatening or fatal bleeding was reported. The duration of
leukopenia and the need for red blood cell transfusions were the same in both arms.
...
Gene Mutation Increases Drug Toxicity, Rejection Risk in Pediatric Kidney Transplants
... transferase.
Adverse side effects most commonly linked to MMF have included gastrointestinal complications (such as diarrhea) or
leukopenia - a drop in white blood cell count that can put patients at higher risk for infections. In some instances, patients have to be taken off the drug or ...
Novel treatments show improvements in survival and response rates for leukemia and lymphoma
... in the FCR arm as compared with 62.3 percent in the FC arm. While FCR was found to cause more neutropenia (33.6 percent versus 20.9 percent) and
leukopenia (24 percent versus 12.1 percent), it did not increase the incidence of severe infections (18.8 percent versus 14.8 percent) as compared with FC. ...
Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma
... in the FCR arm as compared with 62.3 percent in the FC arm. While FCR was found to cause more neutropenia (33.6 percent versus 20.9 percent) and
leukopenia (24 percent versus 12.1 percent), it did not increase the incidence of severe infections (18.8 percent versus 14.8 percent) as compared with FC. ...
FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
... nausea (48% vs 28%), peripheral neuropathy
(47% vs 5%), diarrhea (46% vs 17%), anemia (43% vs 55%), constipation (37%
vs 16%), neuralgia (36% vs 1%),
leukopenia (33% vs 30%), vomiting (33% vs
16%), pyrexia (29% vs 19%), fatigue (29% vs 26%), lymphopenia (24% vs 17%),
anorexia (23% vs 10%), asthenia (21% vs ...
Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting
... commonly occurring adverse reactions by
SC route were nausea (70.5%), anemia (69.5%), thrombocytopenia (65.5%),
vomiting (54.1%), pyrexia (51.8%),
leukopenia (48.2%), diarrhea (36.4%),
fatigue (35.9%), injection site erythema (35.0%), constipation (33.6%),
neutropenia (32.3%) and ecchymosis (30.5%). Other ...
Leukopenia in Medical Technology
Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders
... by 15 to 25 percent. Secondary objectives included safety, duration of
leukopenia and thrombocytopenia, and the number of red blood cell transfusions.
... no life-threatening or fatal bleeding was reported. The duration of
leukopenia and the need for red blood cell transfusions were the same in both arms.
...
Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
... cisplatin for the treatment of patients with MPM were neutropenia
(24%);
leukopenia (16%); anemia (6%); thrombocytopenia (5%); infection
without neutropenia ... with ALIMTA for the
treatment of patients with NSCLC were anemia (8%);
leukopenia (5%);
neutropenia (5%); thrombocytopenia (2%); infection without ...
Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
... nausea (48% vs 28%), peripheral neuropathy (47% vs 5%), diarrhea (46% vs 17%), anemia (43% vs 55%), constipation (37% vs 16%), neuralgia (36% vs 1%),
leukopenia (33% vs 30%), vomiting (33% vs 16%), pyrexia (29% vs 19%), fatigue (29% vs 26%), lymphopenia (24% vs 17%), anorexia (23% vs 10%), asthenia (21% vs ...
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
... (48% vs 28%), peripheral neuropathy (47% vs 5%), diarrhea (46% vs
17%), anemia (43% vs 55%), constipation (37% vs 16%), neuralgia (36% vs
1%),
leukopenia (33% vs 30%), vomiting (33% vs 16%), pyrexia (29% vs 19%),
fatigue (29% vs 26%), lymphopenia (24% vs 17%), anorexia (23% vs 10%),
asthenia (21% vs ...
Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
... insomnia; alopecia (hair loss); a reaction at the site of
injection; changes in blood liver function tests and in blood cell counts,
including
leukopenia (low white blood cell count), thrombocytopenia (low
platelet count) and neutropenia (low neutrophil count); thyroiditis
(inflammation of the thyroid ...
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
... phosphatase (68%), elevated serum creatinine
(57%), lymphopenia (53%), hypophosphatemia (49%), thrombocytopenia (40%),
elevated AST (38%), and
leukopenia (32%).
Most common Grades 3/4 adverse events included asthenia (11%), dyspnea
(9%), hemoglobin decreased (20%), lymphocytes decreased (16%), ...
New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
... phosphatase (68%), elevated serum creatinine
(57%), lymphopenia (53%), hypophosphatemia (49%), thrombocytopenia (40%),
elevated AST (38%), and
leukopenia (32%).
Most common Grades 3/4 adverse events included asthenia (11%), dyspnea
(9%), hemoglobin decreased (20%), lymphocytes decreased (16%), ...
Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
... phosphatase (68%), elevated serum creatinine
(57%), lymphopenia (53%), hypophosphatemia (49%), thrombocytopenia (40%),
elevated AST (38%), and
leukopenia (32%). Most common grades 3/4 adverse
events included asthenia (11%), dyspnea (9%), hemoglobin decreased (20%),
lymphocytes decreased (16%), glucose ...
GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
... CINV is 24 hours to 120 hours
following treatment.(8)
The most commonly reported all-cause adverse events in the treatment
arms were neutropenia,
leukopenia and anemia, which occurred at a higher
rate in the casopitant arms. The incidence of serious neutropenia adverse
events was two percent in the active ...
Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer
... or life-threatening) adverse events were neutropenia
(a decrease in the number of granular white blood cells, 54%); febrile
neutropenia, 5.5%,
leukopenia (low white blood cell count, 14%), and
weakness/fatigue (10%; no Grade 4 events). Grade 3 peripheral neuropathy (a
functional disturbance or damage ...
Leukopenia in Medical Dictionary
Leukopenia
...
leukopenia - An abnormally low white blood cell count. ... Slightly higher counts are seen in children.
leukopenia : Lower than the normal amount of white blood ... For: search help Printer-Friendly Format ...
leukopenia : An abnormally low number of white blood cells ...
Thrombocytopenia
... medications known to cause thrombocytopenia or
leukopenia as a side effect. Note: Clinical trials ... by anorexia , diarrhea , loss of hair ,
leukopenia , thrombocytopenia , growth retardation , and ... ( anemia ), low white blood cell count (
leukopenia ) with a tendency to infection , and low ...
Hernia
... that stimulates thyroid hormone production. pan immunity ; pan
leukopenia ; pan
leukopenia virus of cats; panlobular emphysema ; panmixis; panmyelophthisis; ...
Leukocytes
... blood cells, the blood cells responsible for fighting infection .
leukopenia ... Granular leukocytes -- they are better known as granulocyte s ... infections , inflammation of mammary glands , intestinal antiseptic,
leukopenia (reduction in blood leukocytes ), ... identified to be correlated ...
Neuritis
... panic ulated; panic um; panidiomorphic; panidrosis; pan immunity ; pan
leukopenia ; pan
leukopenia virus of cats; panlobular emphysema ; panmixis; panmyelophthisis; ...
Acute myelogenous leukemia
... in patients being treated for acute myelogenous leukemia . is characterized by low red blood cells ( anemia ), low white blood cell count (
leukopenia ) with a tendency to infection , and low platelet count ( thrombocytopenia ) with bleeding problems. MDS may progress and transform into acute ...
Anorexia
... Zantryl (ION Labor atories). Graft vs Host Disease - The clinical entity characterized by anorexia , diarrhea , loss of hair ,
leukopenia , thrombocytopenia , growth retardation , and eventual death brought about by the GRAFT VS HOST REACTION. Starving for Control: The Truth ...
Diarrhea
... for pain relief during an attack. Graft vs Host Disease - The clinical entity characterized by anorexia , diarrhea , loss of hair ,
leukopenia , thrombocytopenia , growth retardation , and eventual death brought about by the GRAFT VS HOST REACTION. Gastrointestinal (e.g., ...
Diplopia
... extensive, but use of this drug is limited in the cancer population because of concern that it causes bone marrow suppression, in particular
leukopenia . Other common adverse effects include nystagmus , dizziness , diplopia , ... ...
Folliculitis
... elevations or bumps on the skin ) that may grow together to form plaques. eosinophil ic leukocyte; eosinophil ic leukocytosis; eosinophil ic
leukopenia ; eosinophil ic lung disease ; eosinophil ic meningitis ; eosinophil ic meningo encephalitis ; eosinophil ic pneumonia ; eosinophil ic ...
More>>
Leukopenia in Biological News
Leukopenia in Biological Technology
FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
... included: neutropenia (Grade 3/4: 54%) and
leukopenia (Grade 3/4:
49%). (Phase III, Combination Trial: ... included: neutropenia (Grade 3/4: 68%) and
leukopenia (Grade
3/4: 57%). Comparative treatment-related ... capecitabine alone
included: neutropenia 11% and
leukopenia 6%. IMPORTANT SAFETY INFORMATION TOXICITY IN ...
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
... (73%), diarrhea (72%), and nausea (55%). The most common
grade 3/4 adverse events (greater than or equal to 10%) included: diarrhea
(22%),
leukopenia (17%), asthenia/malaise (16%), and acneform rash (14%)
Important Safety Information for ALIMTA
ALIMTA is approved by the FDA in combination with ...
EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
... commonly occurring adverse reactions by
SC route were nausea (70.5%), anemia (69.5%), thrombocytopenia (65.5%),
vomiting (54.1%), pyrexia (51.8%),
leukopenia (48.2%), diarrhea (36.4%),
fatigue (35.9%), injection site erythema (35.0%), constipation (33.6%),
neutropenia (32.3%) and ecchymosis (30.5%). Other ...
FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
... insomnia; alopecia (hair loss); a reaction at the site of
injection; changes in blood liver function tests and in blood cell counts,
including
leukopenia (low white blood cell count), thrombocytopenia (low
platelet count) and neutropenia (low neutrophil count); thyroiditis
(inflammation of the thyroid ...
Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
... one patient is too early to
evaluate. There have been no episodes of Grade 4 (i.e., life-threatening)
side-effects. Four patients experienced Grade 3
leukopenia (i.e., reduction
in white blood cell count), and 1 patient had Grade 3 thrombocytopenia
(i.e., reduction in platelet count). "Our goal with this ...
Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
... the most commonly occurring adverse reactions
were nausea (70.5%), anemia (69.5%), thrombocytopenia (65.5%), vomiting
(54.1%), pyrexia (51.8%),
leukopenia (48.2%), diarrhea (36.4%), fatigue
(35.9%), injection site erythema (35.0%), constipation (33.6%), neutropenia
(32.3%) and ecchymosis (30.5%). Other ...